JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance

U.S. Markets open in 2 hrs 21 mins

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
114.15-0.05 (-0.04%)
At close: 4:00PM EST

114.86 0.71 (0.62%)
Pre-Market: 5:09AM EST

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close114.20
Bid0.00 x
Ask0.00 x
Day's Range114.08 - 115.03
52 Week Range96.04 - 126.07
Avg. Volume7,064,373
Market Cap310.55B
PE Ratio (TTM)20.04
Earnings DateN/A
Dividend & Yield3.20 (2.80%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com51 minutes ago

    Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment

    Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.

  • Investopedia2 hours ago

    Johnson & Johnson Earnings Out Tuesday, What to Expect?

    Having beaten Wall Street's earnings estimates in twelve straight quarters, JNJ has maintained its growth momentum in the face of competitive pressure.

  • Reuters3 hours ago

    Actelion drug fails trial, denting revenue potential

    Actelion's Opsumit drug missed the main target in a late-stage study of patients with pulmonary arterial hypertension due to Eisenmenger Syndrome, the Swiss drugmaker said on Monday. Actelion had been conducting the Phase III trial on 226 patients as part of its push to expand clinical use of Opsumit -- its follow-on medicine to blockbuster PAH drug Tracleer that has lost patent protection -- for patients suffering from different forms of the deadly heart-lung ailment.